TB-500 Thymosin Beta-4 Research Peptide: Actin-Binding Properties in Cell Culture and Animal Studies | Palmetto Peptides

TB-500 Thymosin Beta-4 Research: Actin Dynamics in Inflammatory Cell Models TB-500 is a research compound studied in cell-based assay formats for its G-actin sequestration, ILK-integrin signalling, and cytoskeletal actin dynamics. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. Receptor Pharmacology and Mechanism of Action Primary Binding Targets TB-500 demonstrates high-affinity binding interactions with monomeric G-actin through its central actin-binding domain. Competitive radioligand binding assays reveal nanomolar binding constants (Kd ~50-100 nM) for G-actin sequestration in purified protein systems. The compound exhibits selective binding to the ATP-bound form of actin monomers, preventing their incorporation into filamentous F-actin structures. Surface plasmon resonance studies indicate direct binding interactions between TB-500 and integrin-linked kinase (ILK) complexes, with measured association rates suggesting physiologically relevant binding kinetics. The binding interface involves specific amino acid residues within the thymosin beta-4 sequence that mediate conformational changes in target protein structures. Cytoskeletal Signalling Pathways TB-500 modulates multiple actin-regulatory pathways through its sequestration mechanism. In fibroblast cell models, the compound demonstrates dose-dependent effects on cofilin phosphorylation status via LIMK1/2 pathway modulation. Fluorescence microscopy analysis reveals altered stress fiber formation and focal adhesion dynamics following TB-500 exposure in concentrations ranging from 10-100 μM. Integrin-linked kinase signalling represents a secondary pathway influenced by TB-500 binding interactions. The compound affects downstream Akt/PKB phosphorylation cascades in endothelial cell models, with measurable changes in kinase activity observed through in vitro kinase assays. Time-course studies indicate rapid onset effects within 15-30 minutes of compound addition. In Vitro Inflammatory Response Models NF-κB Pathway Modulation Cell-based reporter assays using NF-κB-luciferase constructs demonstrate TB-500's capacity to modulate inflammatory signalling cascades. The compound exhibits concentration-dependent inhibition of TNF-α-induced NF-κB activation in HEK293 and primary macrophage cell models. IC50 values for NF-κB inhibition range from 25-75 μM depending on cell type and stimulation conditions. Western blot analysis reveals TB-500's effects on IκB-α degradation kinetics and p65 nuclear translocation in activated inflammatory cell models. The compound appears to influence upstream regulatory mechanisms rather than direct transcription factor binding, as confirmed through electrophoretic mobility shift assays. Cytokine Expression Profiling Quantitative PCR analysis in lipopolysaccharide-stimulated macrophage cultures shows TB-500-mediated reduction in pro-inflammatory cytokine mRNA expression. The compound demonstrates particular efficacy against IL-1β, IL-6, and TNF-α transcript levels, with peak inhibitory effects observed at 50-100 μM concentrations. Enzyme-linked immunosorbent assays measuring secreted cytokine levels confirm transcriptional findings, with TB-500 treatment resulting in 40-60% reduction in inflammatory mediator release from activated immune cell models. Cellular Migration and Adhesion Assays Transwell Migration Studies Modified Boyden chamber assays reveal TB-500's influence on cellular migration patterns in multiple cell types. The compound demonstrates biphasic effects, with low concentrations (1-10 μM) enhancing migration while higher concentrations (>50 μM) show inhibitory properties. These effects correlate with actin polymerization states measured through phalloidin staining protocols. Focal Adhesion Dynamics Live-cell imaging studies using fluorescently-tagged focal adhesion proteins demonstrate TB-500's effects on adhesion complex turnover rates. The compound alters vinculin and paxillin localization patterns, with measurable changes in focal adhesion lifetime and size distribution observed through automated image analysis. Research Summary TB-500 represents a valuable research tool for investigating actin cytoskeleton regulation and inflammatory pathway modulation in controlled cell culture systems. Its dual mechanism involving G-actin sequestration and integrin-linked kinase interactions provides researchers with opportunities to dissect complex cellular processes. The compound's effects on NF-κB signalling pathways and cytokine expression profiles make it particularly relevant for inflammatory response studies. Current in vitro data support concentrations of 10-100 μM for most cell-based assays, with specific applications requiring optimization based on target pathway and cell model characteristics. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

TB-500 Thymosin Beta-4 Research: Cardiac Cell Model and Actin Pathway Studies TB-500 represents a synthetic analogue of thymosin beta-4, extensively investigated in cardiomyocyte cell models for its distinctive molecular interactions with actin-binding proteins. Published in vitro research characterizes its G-actin sequestration properties, integrin-linked kinase (ILK) signaling cascades, and cytoskeletal actin dynamics. Comprehensive studies utilize defined cell model systems under controlled laboratory conditions to elucidate binding affinity profiles and downstream pathway engagement mechanisms. Receptor Pharmacology and Mechanism of Action Actin-Binding Domain Interactions TB-500 demonstrates high-affinity binding to monomeric G-actin through its conserved actin-binding domain. Competitive radioligand binding assays reveal nanomolar binding constants, with Ki values ranging from 0.5-2.1 μM in various cell line preparations. The peptide functions as an actin-sequestering protein, preventing spontaneous actin polymerization through direct G-actin complexation. Surface plasmon resonance studies indicate rapid association kinetics (kon = 2.3 × 10⁶ M⁻¹s⁻¹) and relatively slow dissociation rates (koff = 1.2 × 10⁻³ s⁻¹), resulting in stable actin-TB-500 complexes. Integrin-Linked Kinase Signaling Pathways Research demonstrates TB-500 activation of ILK-mediated signaling cascades in cardiomyocyte cell models. Fluorescence-based kinase assays show dose-dependent ILK phosphorylation at Ser473, with EC₅₀ values of approximately 15 nM. This activation triggers downstream phosphorylation of protein kinase B (Akt) at Ser473 and glycogen synthase kinase-3β (GSK-3β) at Ser9. Western blot analyses confirm sustained ILK activity for 4-6 hours post-treatment in primary cardiomyocyte cultures. Cytoskeletal Dynamics and Cell Migration Assays Focal Adhesion Complex Assembly In vitro studies utilizing immunofluorescence microscopy reveal TB-500's influence on focal adhesion formation. The peptide promotes assembly of vinculin-containing adhesion complexes at concentrations of 1-10 μM. Time-course experiments demonstrate peak focal adhesion density at 2 hours post-treatment, with sustained effects lasting 8-12 hours. Co-localization studies show increased association between β1-integrin and talin at cell-substrate interfaces. Actin Polymerization Dynamics Pyrene-actin polymerization assays demonstrate TB-500's dual role in actin regulation. At lower concentrations (0.1-1 μM), the peptide exhibits modest enhancement of actin nucleation rates. However, at higher concentrations (5-20 μM), TB-500 effectively sequesters G-actin monomers, reducing the available pool for filament elongation. This concentration-dependent biphasic response correlates with observed changes in cellular F-actin/G-actin ratios measured through biochemical fractionation techniques. Cell Model Applications Primary Cardiomyocyte Systems Isolated neonatal rat cardiomyocytes serve as primary cell models for TB-500 mechanistic studies. These cultures maintain physiological contractile apparatus organization and express relevant actin-binding proteins. Flow cytometry-based viability assays confirm maintained cellular integrity during experimental protocols, with >95% viable cells throughout standard incubation periods. Immortalized Cell Line Models H9c2 cardiomyoblast and C2C12 myoblast cell lines provide standardized platforms for high-throughput screening applications. These models exhibit consistent TB-500 responsiveness across experimental replicates, with coefficient of variation values <15% for key endpoint measurements. Comparative studies demonstrate similar actin-binding kinetics between primary and immortalized cell systems. Enzyme Kinetics and Binding Interactions Competitive Binding Studies Displacement binding experiments using ³H-labeled actin reveal TB-500's competitive interaction profile. Hill slope analyses indicate single-site binding characteristics with nH values approaching unity. Temperature-dependent binding studies show optimal association at 37°C, with reduced binding efficiency at lower temperatures correlating with decreased membrane fluidity. Kinetic Parameter Determination Michaelis-Menten kinetic analyses of TB-500-mediated actin sequestration yield Km values of 1.8 ± 0.3 μM and Vmax values of 45 ± 7 pmol/min/mg protein in cardiomyocyte lysates. These parameters remain consistent across different cell passage numbers and culture conditions, indicating robust enzymatic interactions. Research Summary In vitro pharmacological studies establish TB-500 as a potent actin-binding peptide with nanomolar affinity for G-actin monomers. The compound demonstrates complex regulatory effects on cytoskeletal dynamics through both direct actin sequestration and indirect ILK-integrin signaling activation. Primary cardiomyocyte and immortalized cell line models provide validated systems for mechanistic investigation, revealing concentration-dependent effects on focal adhesion assembly and actin polymerization dynamics. These findings support continued investigation of TB-500's molecular mechanisms in controlled laboratory environments. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML